Deferred Tax Assets, Valuation Allowance of Crinetics Pharmaceuticals, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Crinetics Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Crinetics Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $392,031,000, a 39% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Crinetics Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $392,031,000 +$110,247,000 +39% 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q4 2024 $281,784,000 +$96,907,000 +52% 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q4 2023 $184,877,000 +$58,929,000 +47% 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q4 2022 $125,948,000 +$40,467,000 +47% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q4 2021 $85,481,000 +$34,609,000 +68% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q4 2020 $50,872,000 +$22,277,000 +78% 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q4 2019 $28,595,000 +$16,018,000 +127% 31 Dec 2019 10-K 30 Mar 2021 2020 FY
Q4 2018 $12,577,000 +$7,719,000 +159% 31 Dec 2018 10-K 09 Mar 2020 2019 FY
Q4 2017 $4,858,000 31 Dec 2017 10-K 13 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.